Valeant Pharma (VRX) Reports Q2 EPS of $1.91

Valeant Pharma (NYSE: VRX) reported Q2 EPS of $1.91, versus $1.34 reported last year. Revenue for the quarter came in at $1.99 billion, versus $1.06 billion reported last year.

For earnings history and earnings-related data on Valeant Pharma (VRX) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• JPMorgan Upgrades Tyson (TSN) to Overweight
• Barclays Starts Tower Semiconductor (TSEM) at Overweight